BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Odronextamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Odronextamab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07128641-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270102
DTEND;VALUE=DATE:20270103
SUMMARY:Odronextamab: Phase 2 readout est. (NCT07128641)
DESCRIPTION:Odronextamab\, phase 2\, Follicular Lymphoma.\nStudy: Odronexta
 mab in Low Tumor Volume Advanced FL\nEstimated primary completion: 2 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/odronextamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 28641
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06735664-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Odronextamab: Phase 1 readout est. (NCT06735664)
DESCRIPTION:Odronextamab\, phase 1\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Zanubrutinib in Combination With Odronextamab for the Treatment of Patien
 ts With Richter's Transformation\nEstimated primary completion: 13 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/odronextamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673
 5664
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091254-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091254)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works C
 ompared to Rituximab Combined With Different Types of Chemotherapy for Adu
 lt Participants With Previously Untreated Follicular Lymphoma\nEstimated p
 rimary completion: 29 February 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06091254
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091865-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091865)
DESCRIPTION:Odronextamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy:
  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works
  and How Safe it is Against Rituximab Combined With Chemotherapy\, in Adul
 t Patients With Previously Untreated Diffuse Large B-cell Lymphoma\nEstima
 ted primary completion: 30 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06091865
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784726-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06784726)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CA
 R-T\nEstimated primary completion: 10 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06784726
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06230224-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06230224)
DESCRIPTION:Odronextamab\, phase 3\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A
  Trial to Learn How Effective and Safe Odronextamab is Compared to Standar
 d of Care for Adult Participants With Previously Treated Aggressive B-cell
  Non-Hodgkin Lymphoma\nEstimated primary completion: 29 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/odronextamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06230224
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854159-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06854159)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B
 -cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy\n
 Estimated primary completion: October 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06854159
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05685173-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290216
DTEND;VALUE=DATE:20290217
SUMMARY:Odronextamab: Phase 1 readout est. (NCT05685173)
DESCRIPTION:Odronextamab\, phase 1\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A
  Trial to Study if REGN5837 in Combination With Odronextamab is Safe for A
 dult Participants With Aggressive B-cell Non-Hodgkin Lymphomas\nEstimated 
 primary completion: 16 February 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05685173
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097364-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290729
DTEND;VALUE=DATE:20290730
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06097364)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolera
 ted and How Well it Works Compared to Rituximab Combined With Chemotherapy
  for Adult Participants With Follicular Lymphoma\nEstimated primary comple
 tion: 29 July 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 dronextamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06097364
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975787-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290910
DTEND;VALUE=DATE:20290911
SUMMARY:Odronextamab: Phase 1 readout est. (NCT06975787)
DESCRIPTION:Odronextamab\, phase 1\, Systemic Lupus Erythematosus.\nStudy: 
 Dose Escalation Study With Bispecific Antibodies in Adult Participants Wit
 h Lupus Nephritis\nEstimated primary completion: 10 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/odronextamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06975787
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887750-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Odronextamab: Phase 1/2 readout est. (NCT07887750)
DESCRIPTION:Odronextamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStud
 y: REGN9220 in Combination With Odronextamab in Adult Participants With Re
 lapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)\nEst
 imated primary completion: 1 November 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07887750
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06149286-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06149286)
DESCRIPTION:Odronextamab\, phase 3\, Follicular Lymphoma.\nStudy: A Trial t
 o Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Be
 tter Than Rituximab Combined With Lenalidomide in Adult Participants With 
 Follicular Lymphoma and Marginal Zone Lymphoma\nEstimated primary completi
 on: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/od
 ronextamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06149286
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05991388-5820@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20310501
DTEND;VALUE=DATE:20310502
SUMMARY:Odronextamab: Phase 2/3 readout est. (NCT05991388)
DESCRIPTION:Odronextamab\, phase 2/3\, B-Cell Non-Hodgkin Lymphoma.\nStudy:
  A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and 
 Refractory B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 1 Ma
 y 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/odronextamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0599
 1388
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
